CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology ...
A wearable device pairs glucose-responsive insulin with algorithmic pump control, creating dual safety loops that reduced ...
Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program REDWOOD CITY, ...
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (RZLT) (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by ...
Individualized nutrition therapy is recommended. Monitoring carbohydrate intake is critical to achieving glycemic control. Comprehensive nutrition education is recommended at diagnosis with annual ...
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, ...
Hypoglycemia is a condition marked by an abnormally low level of blood sugar (glucose), your body’s main energy source. It is commonly associated with the treatment of diabetes, although people ...
Disparities Between Provider Assessment and Documentation of Care Needs in the Care of Adolescent and Young Adult Patients With Sarcoma We used the Institute for Healthcare Improvement (IHI) Model for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback